

# Determinants of Multidrug Resistance Tuberculosis: Systemic Review and Meta-analysis

Kaleab Tesfaye Tegegne<sup>1†</sup>, Andualem Zenebe<sup>1</sup>, Abiyu Ayalew Assefa<sup>1</sup>, Mekibib Kassa Tessema<sup>2</sup>, Eleni Tesfaye Tegegne<sup>3</sup>, Alelign Tadele Abebe<sup>4</sup>, Berhanu Bifato<sup>1</sup>, Muse Rike<sup>5</sup>

## ABSTRACT

**Objective:** The aim of this systemic review and meta-analysis was to determine demographic, behavioral and clinical risk factors for multiple drug-resistant 19 studies were included in the systemic review and meta-analysis.

**Materials and Methods:** Search engines; PubMed/Medline, Web of Science, Scopus and Google scholar were used to search related literatures on MDR TB and selected determinates of MDRTB. All data were independently extracted. We used a random-effects model according to the DerSimonian and Laird method.

**Results:** The risk of having MDR-TB in patients who have informal education was 0.67 times lower than that of patients who have formal education (RR=0.67; 95% CI, 0.46 to 0.96). The risk of having MDR-TB in patients who have Diabetes Mellitus was 1.33 times higher than that of patients who have no Diabetes Mellitus (RR of 1.33 and 95% CI, 1.01 to 1.77)

**Conclusion:** This systemic review and meta-analysis indicated that the risk of having MDR-TB in patients who have informal education was 0.67 times lower than that of patients who have formal education and the risk of having MDR-TB in patients who have Diabetes Mellitus was 1.33 times higher than that of patients who have no Diabetes Mellitus. Our review did not show the presence of an association between MDR TB and other selected variables gender, smoking and alcohol. We recommend interested researchers on MDR TB to do further research on patient's educational level as a risk factor for MDR-TB in order to explain the variation in MDR TB among patients with formal education and patients with informal education.

**Keywords:** Multidrug resistance tuberculosis; Alcohol; Smoking; Diabetes mellitus; Gender; Educational status

## Introduction

Multidrug resistance tuberculosis is a tuberculosis caused by a tubercle bacillus that is resistant to isoniazid and rifampicin [1]. Worldwide, an estimated 10.0 million people diseased with TB in 2018 [2]. In 2018, WHO reported that there were 484,000 incident cases of MDRTB cases and 44.21 (214,000 deaths) [3]. In the world, MDR-TB among TB patients who are new cases and previously treated cases was estimated to be 3.5% and 20.5% respectively [4]. MDR-TB has received increased attention in Africa and it is under-reported [5-6]. In Sub-Saharan Africa the magnitude reaches 14% of the world new MDR-TB cases [5].

In six countries of Africa including (new/ retreatment % respectively) Angola (2.6/18%), DR Congo (2.2/17%), Kenya (1.3/9.4%), Nigeria (4.3/25%), Somalia (8.7/47%) and Zimbabwe (4.6/14%) [4].

In the African Region, the frequency of resistance per country ranged Burundi in the third position with 66% after Rwanda (87%), Democratic Republic of the Congo (68%) [7].

In Ethiopia prevalence of MDR TB is 2.7% and 14.0% in newly and treated previously TB patients respectively [4].

In Ethiopia, many of the MDR-TB patients are undiagnosed due to the poor socioeconomic

<sup>1</sup>Department of Public Health, Hawassa College of Health Science, Hawassa, Ethiopia

<sup>2</sup>Leishmania Research and Treatment Center, University of Gondar, Gondar, Ethiopia

<sup>3</sup>College of Medicine and Health Science, School of Nursing, University of Gondar, Gondar, Ethiopia

<sup>4</sup>Department of Medical Laboratory Technology, Hawassa College of Health Science, Hawassa, Ethiopia

<sup>5</sup>Hawassa College of Health Science, Research and publication Directorate

<sup>†</sup>Author for correspondence: Kaleab Tesfaye Tegegne, Department of Public Health, Hawassa College of Health Science, Hawassa, Ethiopia; Email: kaleabtesfaye35@gmail.com

status of people, low level of knowledge and decreased access to health service.

In Ethiopia the number of patients tested for MDR-TB was <1% of new cases and <4% of retreatment cases [8].

Previous studies identified some risk factors associated with MDRTB like gender [9,10], smoking or other substance misuse and diabetes [11-14].

Previous studies in Ethiopia and China also reported that HIV/AIDS smoking cigarette, and drinking alcohol, overcrowding, and poor adherence to DOTS (Directly Observed Treatment Short-course) program are factors associated with MDR-TB [15-20].

Few authors worldwide had the concern of investigating the patient's educational level as a risk factor for MDR-TB [21,22].

The aim of this systemic review and meta-analysis was to determine demographic, behavioral and clinical risk factors for multiple drug-resistant TB and for this we have selected two demographic variables gender and educational status, two behavioral factors alcohol and smoking and one clinical factor that is Diabetes Mellitus.

## Methodology

### ■ Literature search strategy

These systematic reviews and meta-analyses were done in line with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Guideline [23] and we have done the search for different literatures that include data on magnitude of MDR-TB in relation to two socio demographic variables gender and educational status, two behavioral variables alcohol and smoking and one clinical variable, Diabetes Mellitus.

Search engines; PubMed/Medline, Web of Science, Scopus and Google scholar were used to search related literatures on MDR TB and selected determinates of MDRTB.

Combination of words used to search were; "MDRTB", "Gender and MDRTB", "Diabetes Mellitus and MDRTB", "alcohol and MDRTB", "educational status and MDRTB" and "smoking and MDRTB."

In addition, the reference of selected articles was used to search additional studies not found in our initial search.

### ■ Selection/eligibility criteria

Studies that reported five selected determinants of MDR-TB and this are gender, educational status, alcohol, smoking and Diabetes Mellitus and published in English language regardless of the design and setting were included. Studies were included in the review irrespective of their study year .

### ■ Outcome of interest

MDR-TB is TB that caused by strains of *M. tuberculosis* that are resistant to isoniazid and RMP [4,24].

### ■ Data extraction and quality assessment

The titles and abstracts were assessed for reporting the outcome and for fulfilling the eligible criteria. From studies that fulfill the eligible criteria the following data was extracted using prepared form: Name of author, prevalence of MDR-TB in the selected variables gender, smoking, alcohol, educational status and Diabetes Mellitus.

All data were independently extracted. Returned abstracts were reviewed to check whether they contained relevant information.

Each selected research was assessed using the Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomized studies in meta-analyses [25].

### ■ Data analysis

An outcome of interest was MDR-TB. We used a random-effects model according to the Der Simonian and Laird method [26].

Heterogeneity was assessed by the  $I^2$  and values greater than 50% considered representing significant heterogeneity.

When there is heterogeneity between studies we used random-effect models [27]. Results were presented in forest plots. Publication bias was assessed using funnel plots and Beggs and egggers regression test. Analysis was performed using Rev Man software version 5.3 [28].

## Results

### ■ Studies included

Our initial search using the search terms gave 1170 articles. Out of these, 559 researches which do not match with the aim of the study were excluded after reviewing their titles and abstracts. Then the remaining articles were checked for duplications and 77 articles were selected for

full text review. Of the 77 articles reviewed in full text, 19 articles [29-47] were included in the final analysis based on the inclusion-exclusion criteria and quality assessment and 58 studies were removed prior to analysis for reasons of not reporting at least one variable from the five selected variables to be studied as determinants of MDRTB. The selection process of study is presented in (Figure 1).

### ■ Description of findings

Nineteen studies were included in the systemic review and meta-analysis [29-47]. Ten studies measured magnitude of MDR-TB among Informal and/or formal educated patients [29,30,32,33,35,37,38,44,46,47].

Sixteen studies measured magnitude of MDR-TB among male and/or female patients [29-40, 43, 45-47].

Seven studies measured magnitude of MDR-TB among Diabetes mellitus and/or no diabetes mellitus patients [29, 32, 36, 38, 40, 42, 45].

Eight studies measured magnitude of MDR-TB among alcohol drinking patients and/or no alcohol drinking patients [29-33,35,45,47].

Thirteen studies measured magnitude of MDR-TB among Smoking patients and/or no Smoking patients [29-33,35,37,38,41,42,45-47].

### Gender and MDR TB

The meta-analysis of gender and MDR-TB did not demonstrate a statistically significant association of MDR-TB with Gender (An overall RR of 0.96 and 95% CI, 0.86 to 1.07)

As presented in Figure 2, except for three studies [30,38,39], all other studies showed

no association of MDR-TB to male or female patients.

Heterogeneity testing showed significant variation among the studies ( $I^2=53\%$ ).

### ■ Educational status and MDR TB

The risk of having MDR-TB in patients who have informal education was 0.67 times lower than that of patients who have formal education (overall RR=0.67; 95% CI, 0.46 to 0.96).

The combined effect size indicated that there is a statistically significant association of MDR-TB with educational status of patients, five studies [30,32,37,46,47] were exceptions.

There is heterogeneity between the studies ( $I^2=84\%$ ) (Figure 3).

### ■ Source of heterogeneity for educational status and MDRTB


There is a statistically significant association between effect size and magnitude of informal education as shown in the moderator analysis as prevalence of informal education increase, the effect size for MDRTB decrease ( $B = -3.67$ ,  $p$  value  $<0.0001$ )

### Assessment of publication bias for educational status and MDRTB


We used Beggs test for asymmetry of funnel plot ( $p$  value 0.531) and Eggers regression test ( $p$  value 0.903) to test publication bias and both indicated that there is no publication bias for the meta-analysis of educational status and MDRTB.

### Alcohol and MDR TB


The meta-analysis of Alcohol and MDR-TB did not also demonstrate a statistically significant




**Figure 1:** Flow chart for the process of searching, selection and screening of the systemic review and meta - analysis



**Figure 2:** Risk ratio of multidrug resistant TB (MDR-TB) in relation to Gender status (Male vs Female), a meta-analysis on Determinates of MDR TB.



**Figure 3:** Risk ratio of multidrug resistant TB (MDR-TB) in relation to Gender status (Male vs Female), a meta-analysis on Determinates of MDR TB.



**Figure 4:** Moderator analysis for educational status and MDRTB.

association of MDR-TB with Drinking Alcohol (overall RR of 0.97 and 95% CI, 0.75 to 1.25).

As presented in **Figure 6**, except for two studies [32,33], all other studies showed no association of MDR-TB to Alcohol drinking patients or No alcohol drinking patients.

There is Heterogeneity between the studies ( $I^2=74\%$ ).

### Smoking and MDR TB

The meta-analysis of smoking and MDR-TB did not also demonstrate association of MDR-TB


with smoking status (an overall RR of 1.18 and 95% CI, 0.87 to 1.60)

As presented in **Figure 7**, except for five studies [29, 32, 38, 42, 47], all other studies showed no association of MDR-TB to smoking patients or no smoking patients.


There is Heterogeneity between the studies ( $I^2=87\%$ ).

### Diabetes Mellitus and MDR TB


The meta-analysis of Diabetes Mellitus and MDR-TB showed that there is a statistically




**Figure 5:** Funnel plot for educational status and MD RTB.



**Figure 6:** Risk ratio of multidrug resistant TB (MDR-TB) in relation to drinking alcohol (drinking alcohol vs no drinking alcohol), a meta-analysis on Determinates of MDR-TB.



**Figure 7:** Risk ratio of Multidrug Resistant TB (MDR-TB) in relation to smoking status (smoking vs no smoking), a meta-analysis on Determinates of MDR TB.



**Figure 8:** Risk ratio of Multidrug-Resistant TB (MDR-TB) in relation to Diabetes Mellitus (Diabetes Mellitus vs No Diabetes Mellitus), a meta-analysis on Determinates of MDR TB.

significant association of MDR-TB with Diabetes Mellitus.

The risk of having MDR-TB in patients who have Diabetes Mellitus was 1.33 times higher than that of patients who have no Diabetes Mellitus (an overall RR of 1.33 and 95% CI, 1.01 to 1.77).

As presented in Figure 8, except for three studies [29, 38, 40], all other studies showed no association of MDR-TB to Diabetes Mellitus patients or no Diabetes Mellitus patients.

Heterogeneity testing showed significant variation among the studies (I<sup>2</sup>=66%).

## Discussion

### ■ MDRTB and GENDER

The finding of this systemic review and meta-analysis showed that there is no statistically significant difference between male and female with respect to Multi Drug Resistance

Tuberculosis and our study is similar with previous studies [29,30,32,33,37,38,48-50]. Our finding is not similar with previous studies [39,43,51-53].

The explanations for the association between gender and MDRTB in previous studies are socio economic factors, health seeking behavior, prolonged delays in female patients (due to lack of control at household levels on financial resources), increased immune suppression with pregnancy, lactation and increased magnitude of HIV.

### ■ MDRTB and SMOKING

This systemic review and meta-analysis did not indicate the presence of association between smoking and Multi Drug Resistance Tuberculosis and this is consistent with previous studies [54].

Further studies need to be done on smoking and resistance to anti-tuberculosis drugs [32]. This systemic review and meta-analysis are not similar with previous studies [13,38]

The reason for the difference in findings might be variation in sample size, study design and study participants characteristics

#### ■ ALCOHOL and MDRTB

Our finding showed that there is no statistical significant association between MDRTB and drinking alcohol and we could not found similar findings in our search for literature but our findings is not similar with previous studies [49,55-57].

The explanation for the observed association between alcohol and MDRTB in previous studies is that alcohol drinking is associated with elevated probability of MDR-TB due to decreased adherence immunosuppression and adverse drug effects.

Drinking Alcohol was associated with increased risk of MDR-TB [37,58-59].

#### ■ Diabetes Mellitus and MDRTB

In our systemic review and meta-analysis there is an association between Diabetes Mellitus and MDR TB and our finding is similar with previous studies [29,60].

The findings of this systemic review and meta-analysis are not similar with previous study [61].

The possible explanation for the variation in results might be difference in sample size and study participant's characteristics.

#### ■ Educational Status and MDRTB

Fewer researchers had investigating the educational level of patients and MDR-TB [61-62].

Our systemic review and meta-analysis indicated that the risk of having MDR-TB in patients who have informal education was 0.67 times lower than that of patients who have formal education (overall RR=0.67; 95% CI, 0.46 to 0.96) and our finding is consistent with previous studies [38,39,42]. This study is not similar with previous studies [49,58,59,63-66].

The possible explanation for difference in findings between our review and other studies might be difference in study participants characteristics, sample size and study areas.

#### Conclusion

This systemic review and meta-analysis indicated that the risk of having MDR-TB in patients who

have informal education was 0.67 times lower than that of patients who have formal education and the risk of having MDR-TB in patients who have Diabetes Mellitus was 1.33 times higher than that of patients who have no Diabetes Mellitus.

Our review did not show the presence of association between MDR-TB and other selected variables gender, smoking and alcohol.

We recommend interested researchers on MDRTB to do further research on patient's educational level as a risk factor for MDR-TB in order to explain the variation in MDR-TB among patients with formal education and patients with informal education.

---

#### Data Availability

All data are included in the paper.

---

#### Conflicts of Interest

The authors declare that they have no conflicts of interest.

---

#### Authors' Contributions

Kaleab Tesfaye Tegegne was responsible for conceptualization, project administration, software, supervision, and development of the original drafting of the manuscript. Kaleab Tesfaye Tegegne, Eleni Tesfaye Tegegne, Abiyu Ayalew Assefa, Mekibib Kassa Tessema, Berhanu Bifato, Alelign Tadele Abebe, Muse Rike and Andualem Zenebe were participated in quality assessment of articles, methodology, validation, and screening of research papers. All authors contributed with data analysis, critically revised the paper, and agreed to be accountable for their contribution.

---

#### Acknowledgments

We would like to thank all the primary authors of the included articles.

---

#### Competing of interest

The authors have declared that there is no competing interest.

---

#### Funding

Not any funding received for this work.

# References

1. Caminero JA, editor. Guidelines for clinical and operational management of drug-resistant tuberculosis. 1st ed. Paris, France: International Union Against Tuberculosis and Lung Disease; (2013).
2. United Nations General Assembly. Resolution 73/3: Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. United Nations; (2018).
3. Angelo I, Lanfranco F, Federico G. Drug-resistant tuberculosis 2020: Where we stand. *Appl Sci* 10, 1-17 (2020).
4. World Health Organization. Global tuberculosis report. Geneva: World Health; (2017).
5. Migliori GB, Dheda K, Centis R, et al. Review of multidrug resistant and extensively drug resistant TB: global perspectives with a focus on sub-Saharan Africa. *Trop Med Int Health* 15, 1052-1066 (2010).
6. Ben AY, Nemser B, Singh A, et al. Under reported threat of multidrug-resistant tuberculosis in Africa. *Emerg Infect Dis* 14, 1345-1352 (2008).
7. Daneau G, Gumugboga M, De Rijk P, et al. The majority of patients with multidrug-resistant tuberculosis in sub-Saharan Africa present a concomitant resistance to pyrazinamide. *Int J Microbiol* 5, 46-47 (2016).
8. World Health Organization. Global tuberculosis control report. 20th ed. Geneva: World Health Organization; 2015.
9. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: A systematic review. *Thorax* 61, 158-163 (2006).
10. Ejaz M, Siddiqui AR, Rafiq Y, et al. Prevalence of multi-drug resistant tuberculosis in Karachi, Pakistan: Identification of at risk groups. *Trans R Soc Trop Med Hyg* 104, 511-517 (2010).
11. Casal M, Vaquero M, Rinder H, et al. A case-control study for multidrug-resistant tuberculosis: Risk factors in four European countries. *Microb Drug Resist* 11, 62-67 (2005).
12. Suarez-Garcia I, Rodriguez-Blanco A, Vidal-Perez JL, et al. Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. *Eur J Clin Microbiol Infect Dis* 28, 325-330 (2009).
13. World health Organization, International Union Against Tuberculosis and Lung Disease. A WHO/The Union Monograph on TB and Tobacco control. Geneva; 2007.
14. Fisher-Hoch SP, Whitney E, McCormick JB, et al. Type 2 diabetes and multidrug-resistant tuberculosis. *Scand J Infect Dis* 40, 888-893 (2008).
15. Abdella K, Abdissa K, Kebede W, et al. Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia. *BMC public health* 15, 1-7 (2015).
16. Meskel DW, Abate G, Lakew M, et al. Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital. *Ethiop Med J* 46, 219-225 (2008).
17. Abate D, Taye B, Abseno M, et al. Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in Addis Ababa, Ethiopia. *BMC Res Notes* 5:462 (2012).
18. Mesfin EA, Beyene D, Tesfaye A, et al. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multidrug-resistant tuberculosis suspected patients from Ethiopia. *PLoS ONE* 13, e0197737 (2018).
19. Hirpa S, Medhin G, Girma B, et al. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study. *BMC Public Health* 28; 13, 782 (2013).
20. Deressa MA, Demissie M. Risk factors of multi-drug-resistant tuberculosis in Addis Ababa, Ethiopia: A matched case-control study. *Open Access Libr J* 1, 1-8 (2014).
21. Al Jarad N, Parastatides S, Paul EA, et al. Characteristics of patients with drug resistant and drug sensitive tuberculosis in East London between 1984 and 1992. *Thorax* 49, 808-810 (1994).
22. Murray J, Sonnenberg P, Shearer S, et al. Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with high prevalence of HIV infection. *S Afr Med J* 90, 381-386 (2000).
23. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. *PLoS Med* 6, e1000097 (2009).
24. World Health Organization. Definitions and reporting framework for tuberculosis-2013 revision. Geneva: WHO press; 2013.
25. G Wells, B Shea, DO Connell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomized studies in meta-analyses, Ottawa Hospital Research Institute, Ottawam, Canada; 2009.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 7, 177-188 (1986).
27. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 327, 557-560 (2003).
28. Review Manager 5 (RevMan 5) [Computer program]. Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014
29. Arnaud Iradukunda, Gabin NDAYISHIMIYE, Darlene SINARINZI, et al. Keys factors influencing multidrug-resistant tuberculosis: A mixed effects modelling study in Burundi 2020; 1-16 (2020).
30. Assefa D, Seyoum B, Oljira L. Determinants of multidrug-resistant tuberculosis in Addis Ababa, Ethiopia *Infection and Drug Resistance* 10, 209-213 (2017).
31. B. Baya, Achenbach C, Kone B et al. Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. *Int J Infect Dis* 81, 149-155 (2019).
32. Fregona G, Cosme LB, Moreira CMM, et al. Risk factors associated with multidrug-resistant tuberculosis in Espirito Santo, Brazil. *Rev Saude Publica* 51, 41 (2017).
33. G. Mulisa, Tilaye Workneh, Niguse Hordofa et al. Multidrug-resistant Mycobacterium tuberculosis and associated risk factors in Oromia Region of Ethiopia. *Int J Infect Dis* 39, 57-61 (2015).
34. Glasauer S, Altmann D, Hauer B, et al. (2019) First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017. *PLoS ONE* 14, e0217597 (2019).
35. Herman Owuor, Weyenga. Factors associated with multi-drug resistant tuberculosis in Kenya. 1-113 (2011).
36. Liang Libo, Qunhong Wu, Lijun Gao, et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. *Thorax* 67, 632e638 (2012).
37. Mekonnen F, Tessema B, Moges F, et al. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia. *BMC Infect Dis* 15, 1-6 (2015).
38. Rifat M, Milton AH, Hall J, et al. Development of multidrug resistant tuberculosis in Bangladesh: A case-control study on risk factors. *PLoS ONE* 9, e105214 (2014).
39. Vashakidze L, Salakaia A, Shubladze N, et al. Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia. *Int J Tuberc Lung Dis* 13, 1148-1153 (2009).
40. Wijayanto, Arnanda R, Thamrin E. Risk factors for development of multidrug-resistant tuberculosis among relapsed patients in west papua, indonesia: A descriptive and analytical study. *Int J App Pharm* 11, 50-55 (2019).
41. Hirama T, Sabur NF, Derkach P, et al. Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010-2016. *Can Commun Dis Rep* 46, 84-92 (2020).

42. Barroso Clara E, Rosa Maria Salani Mota, Raimunda Oliveira Santos, et al. Risk factors for acquired multidrug-resistant tuberculosis. *J Pneumologia* 29, 1-10 (2003).
43. Nigus DM, Lingerew WM, Beyene BA, et al. Prevalence of multi drug resistant tuberculosis among presumptive multi drug resistant tuberculosis cases in Amhara National Regional State, Ethiopia. *J Mycobac Dis* 4, 152 (2014).
44. Baghaei P, Tabars P, Chitsaz E et al. Risk Factors Associated with Multidrug-Resistant Tuberculosis. *Tanaffos* 8, 17-21 (2009).
45. Omar Sald Elmi, Habsah Hasan, Sarimah Abdullah, et al. Multidrug-resistant tuberculosis and risk factors associated with its development: a retrospective study. *J Infect Dev Ctries* 9, 1076-1085 (2015).
46. Tenzin C, Chansatitporn N, Dendup T, et al. Factors associated with multidrug-resistant tuberculosis (MDR-TB) in Bhutan: A nation wide case-control study. *PLoS ONE* 15, e0236250 (2020).
47. Lema N, Mbelele P, Majigo M, et al. Risk factors associated with multidrug resistant tuberculosis among patients referred to Kibong'oto Infectious Disease Hospital in northern Tanzania. *Tanzan J Health Res* 18, 1-8 (2016).
48. Demile B, Zenebu A, Shewaye H, et al. Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia. *BMC Infect Dis* 18, 1-10 (2018).
49. Desissa F, Workineh T, Beyene T. Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia. *BMC Public Health* 18, 1-6 (2018).
50. Abebe G, Abdissa K, Abdissa A, et al. Relatively low primary drug resistant tuberculosis in southwestern Ethiopia. *BMC Res Notes* 5, 2-6 (2012).
51. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: A systematic review. *Thorax* 61, 158-163 (2006).
52. Lomtadze N, Aspindzelashvili R, Janjgava M, et al. Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: A population-based study. *Int J Tuberc Lung Dis* 13, 68-73 (2009).
53. Ejaz M, Siddiqui AR, Rafiq Y, et al. Prevalence of multi-drug-resistant tuberculosis in Karachi, Pakistan: Identification of at risk groups. *Trans R Soc Trop Med Hyg* 104, 511-517 (2010).
54. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: A prospective cohort study. *Lancet* 380, 1406-1417 (2012).
55. Garcia Rodriguez JF, Marino Callejo A, Lorenzo Garcia MV, et al. Resistance of *Mycobacterium tuberculosis* in Ferrol, Spain. Associated factors. *Med Clin (Barc)* 113, 572-574 (1999).
56. Torres L. Resistance of *Mycobacterium tuberculosis* in Zaragoza, Spain (1993-1997) and related factors. *Med Clin (Barc)* 115, 605-609 (2000).
57. Fiúza de Melo FA, Afune JB, Ide Neto J, et al. Características da TBMR num serviço de referência: influência sobre o controle do tratamento. *J Pneumol* 26, S94-5 (2000).
58. Hamusse SD, Teshome D, Hussen MS, et al. Primary and secondary anti tuberculosis drug resistance in Hitossa District of ArsiZone, Oromia regional state, Central Ethiopia. *BMC Public Health* 16, 1-10 (2016).
59. Liang Y, Harris FL, Brown LAS. Alcohol induced mitochondrial oxidative stress and alveolar macrophage dysfunction. *Biomed Res Int* 2014, 1-14 (2014).
60. Tegegne BS, Mengesha MM, Teferra AA, et al. Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis. *Syst Rev* 7, 161 (2018).
61. Maja S, Dejana V, Dragan B et al. Risk factors for smultidrug-resistant tuberculosis among tuberculosis patients in Serbia: a case-control study. *BMC Public Health* 18:1-8 (2018).
62. Murray J, Sonnenberg P, Shearer S, et al. Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with high prevalence of HIV infection. *S Afr Med J* 90, 381-386 (2000).
63. Kibret KT, Moges Y, Memiah P, et al. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-plus: A systematic review and meta-analysis of published studies. *Infect Dis Poverty* 6, 1-8 (2017).
64. Workicho A, Kassahun W, Alemseged F. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: A case-control study. *Infect Drug Resist* 10, 91-96 (2010).
65. Lv XT, Lu XW, Shi XY, et al. Prevalence and risk factors of multi-drug resistant tuberculosis in Dalian. *China J Int Med Res* 45, 1779-1786 (2017).
66. Zhao JN, Zhang XX, He XC, et al. Multidrug resistant tuberculosis in patients with chronic obstructive pulmonary disease in China. *PLoS One* 10, e0135205 (2015).